• Biotech
  • Service & Technology

Research Coverage

  • Actinium Pharmaceuticals, Inc. (ATNM)
  • Ambrx Biopharma Inc. (AMAM) 
  • Augmedix Inc. (AUGX) 
  • Azenta, Inc. (AZTA)
  • Checkpoint Therapeutics, Inc. (CKPT)
  • Cryoport, Inc. (CYRX)
  • CytoSorbents Corporation (CTSO)
  • Fusion Pharmaceuticals, Inc. (FUSN)
  • Hyperfine, Inc. (HYPR)
  • Lantheus Holdings, Inc.(LNTH)
  • Perspective Therapeutics, Inc. (CATX) 
  • Tango Therapeutics, Inc. (TNGX)


  • American Association for Cancer Research
  • Society for Immunotherapy of Cancer
  • American Society of Clinical Oncology
  • Cancer Prevention and Research Institute of Texas


Dr. Yuan Zhi is a Healthcare Equity Senior Research Analyst at B. Riley Securities responsible for the coverage of SMid-cap biotech companies developing cutting-edge therapeutics for Oncology and Ophthalmology, including Radiopharma and Life Sciences Tools companies supporting the biotech innovation. He has 9 years of experience in Healthcare, with a focus on Oncology, Ophthalmology, Radiopharma, and Life Sciences Tools.

He had published 2 peer-reviewed articles in Biochemistry. He also serves as Product Development Peer Reviewer at the Cancer Prevention and Research Institute of Texas.

Prior to B. Riley, he held positions at Sirona Capital and Elanco through investment internship and R&D internship.

Dr. Zhi's a member of American Association for Cancer Research, Society for Immunotherapy of Cancer, and American Society of Clinical Oncology. He received a B.Sc. degree in Chemistry from Wuhan University and a Ph.D. degree in Biochemistry from Texas A&M University. He has passed the CFA level II exam in 2018.

B. Riley Securities is a leading middle market investment bank that provides a full suite of corporate finance, advisory, sales and trading and equity research. Investment banking services include initial, secondary and follow-on offerings, institutional private placements, merger and acquisition (M&A) advisory, SPACs, corporate restructuring and recapitalization. B. Riley is nationally recognized and highly ranked for its proprietary equity research.